Balance Sheet
Cash Flow Statement
Amortization of Deferred ChargesAmortizatization of IntangiblesCapital ExpendituresCash from Financing ActivitiesCash from OperationsChange in Account PayablesChange in Accured ExpensesChange in CashDepreciation & Amortization (CF)Depreciation and DepletionFree Cash FlowGains from Investment SecuritiesGains from Sales and DivestituresNet Cash FlowNet IncomeNon-cash ItemsOther Working Capital ChangesShare-based Compensation
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Q32 Bio (QTTB) Capital Expenditures (2017 - 2025)

Historic Capital Expenditures for Q32 Bio (QTTB) over the last 9 years, with Q3 2025 value amounting to $244000.0.

  • Q32 Bio's Capital Expenditures fell 757.58% to $244000.0 in Q3 2025 from the same period last year, while for Sep 2025 it was $1.0 million, marking a year-over-year increase of 4002.79%. This contributed to the annual value of $856000.0 for FY2024, which is 10284.36% up from last year.
  • As of Q3 2025, Q32 Bio's Capital Expenditures stood at $244000.0, which was down 757.58% from $259000.0 recorded in Q2 2025.
  • In the past 5 years, Q32 Bio's Capital Expenditures registered a high of $1.1 million during Q1 2022, and its lowest value of $6000.0 during Q3 2022.
  • Moreover, its 5-year median value for Capital Expenditures was $244000.0 (2025), whereas its average is $300473.7.
  • As far as peak fluctuations go, Q32 Bio's Capital Expenditures tumbled by 9874.21% in 2022, and later surged by 175000.0% in 2023.
  • Over the past 5 years, Q32 Bio's Capital Expenditures (Quarter) stood at $338000.0 in 2021, then plummeted by 97.34% to $9000.0 in 2022, then surged by 1177.78% to $115000.0 in 2023, then surged by 120.87% to $254000.0 in 2024, then fell by 3.94% to $244000.0 in 2025.
  • Its Capital Expenditures was $244000.0 in Q3 2025, compared to $259000.0 in Q2 2025 and $247000.0 in Q1 2025.